Kidney cancer combo trial halted early – what we know
NCT ID NCT05935748
First seen Nov 12, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This study tested two new drug combinations for people with advanced clear cell kidney cancer that had already been treated. The goal was to see if adding the experimental drug NKT2152 to standard therapies could shrink tumors or slow the disease. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065-6094, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
-
Northwestern University - Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390-9324, United States
-
University of California San Diego
La Jolla, California, 92093, United States
-
University of Michigan-Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.